Taub Institute: Genomics Core
AN NIA-FUNDED ALZHEIMER'S DISEASE RESEARCH CENTER

 

Columbia University
Medical Center
Neurological Institute

710 West 168th Street, 3rd floor
(212) 305-1818


bottom bar
top
make an appointment

Clinical Trials

Clinical Trials Currently Recruiting



Alzheimer's Disease: TTP488-301: azeliragon TTP488 (vTv Therapeutics)
A Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine.
Phase 3. Oral Medication. Once Daily. Duration: 18 months. NCT02080364.
Mild to moderate Alzheimer's Disease (AD). MMSE 21-26. Age ≥ 50.
(Dr. Honig) Call Katrina Cuasay (212) 305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez (212) 305-2371.

Alzheimer's Disease: CREAD Crenezumab (Roche)
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD).
Phase 3. Intravenous Medication. Duration: about 26 months. NCT02670083.
Prodromal to Mild Alzheimer's Disease (AD). MMSE ≥22. Age 50-85.
(Dr. Honig) Call Katrina Cuasay (212) 305-2077, Ruth Tejeda (212) 305-7661, Evelyn Dominguez (212) 305-2371.

Dementia with Lewy Bodies: HEADWAY RVT-101 (Axovant)
Study Evaluating RVT-101 in Subjects With Dementia With Lewy Bodies.
Phase 2. Oral Medication. Once daily. Duration: 6 months. NCT02669433.
Dementia with Lewy Bodies (DLB). MMSE 14-26. Age 50-85.
(Dr. Honig) Call Katrina Cuasay (212) 305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez (212) 305-2371.

Alzheimer's Disease: AVP-786 (Avanir)
Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.
Phase 3. Oral Medication. Duration: 12 weeks. NCT02442778.
Probable Alzheimer's Disease (AD). MMSE 6-26. Age 50-90.
(Dr. Devanand) Call Evan Chunga (646) 774-7202, Jesse Strickler (646) 774-8668.

Huntington's Disease: SIGNAL (Vaccinex)
VX15/2503 Treatment for Huntington's Disease.
Phase 2. Intravenous Medication. Duration: 12 or 16 months. NCT0248167.
Huntington's Disease (HD). Age >21. MoCa >23.

(Dr. Marder) Call Paula Wasserman (212) 305-4597, Ronda Clouse (212) 305-2387.

Huntington's Disease: STAIR (NeuroNEXT)
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease.

Phase 2. Oral Medication. Duration: 12 weeks. NCT02507284.
Huntington's Disease (HD). Age >18.
(Dr. Marder) Call Paula Wasserman (212) 305-4597, Ronda Clouse (212) 305-2387.

Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia
Phase 2/3. Oral Medication. Lithium or placebo. Duration: 12 Weeks. NCT02862210. Frontotemporal Dementia (FTD). MMSE 5-26. Age 40-85
(Dr. Huey) For more information, contact Hannah Silverman (212) 305-6284, hs2971@cumc.columbia.edu.

Mild Cognitive Impairment / Alzheimer’s Disease: AMARANTH AZD3293(LY3314814) (Lilly/AstraZeneca)
An Efficacy and Safety Study of LY3314814 in Early Alzheimer's Disease (AMARANTH)
Phase 2/3. Oral Medication. Once Daily. Duration: 24 months. NCT02245737.
Mild Cognitive Impairment due to Alzheimer’s Disease (AD)/Mild Alzheimer’s Disease (AD). MMSE 20-30. Age 55-85.
(Dr. Honig) For more information, please contact Katrina Cuasay (212) 305-2077, Ruth Tejeda (212) 305-7661, Evelyn Dominguez (212) 305-2371.

Normal At-Risk for Alzheimer’s Disease (Presymptomatic): A4 solanezumab (ADCS/Lilly)
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)
Phase 3. Intravenous Medication. Duration: about 36 months. NCT02008357.
Normal individuals with brain amyloid pathology. MMSE 27-30 (25-30 for education <12 yrs). Age 65-85.
(Dr. Bell) For more information, please contact Katrina Cuasay (212) 305-2077, Ruth Tejeda (212) 305-7661, Evelyn Dominguez (212) 305-2371.

Alzheimer’s Disease: lithium (NIA)
Treatment of Psychosis and Agitation in Alzheimer’s Disease.
Phase 2. Oral Medication: lithium or placebo. Duration: 12 weeks. NCT02129348.
Possible or Probable Alzheimer’s Disease (AD). MMSE 5-26. Age 55-95.
(Dr. Devanand) For more information, contact Evan Chunga (646) 774-7202, Jesse Strickler (646) 774-8668.

Amnestic Mild Cognitive Impairment/Alzheimer’s Disease: donepezil (NIA)
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly.
Phase 4. Oral Medication. Duration: about 12 months. NCT01951118.
Amnestic Mild Cognitive Impairment (MCI) or Probable Alzheimer’s Disease (AD). MMSE 18-30. Age 55-95.
(Dr. Devanand) For more information, contact Evan Chunga (646) 774-7202, Jesse Strickler (646) 774-8668.

Progressive Supranuclear Palsy: C2N-8E12-WW-104 (C2N)
A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy.
Phase 1. Intravenous Medication. Duration: about 4 months. NCT02494024.
Progressive Supranuclear Palsy (PSP). Age 50-85.
(Dr. Honig) For more information, contact Katrina Cuasay (212) 305-2077, Ruth Tejeda (212) 305-7661, Evelyn Dominguez (212) 305-2371.

Huntington’s Disease: LEGATO-HD (Teva)
A Clinical Study in Subjects with Huntington's Disease to Assess the Efficacy and Safety of Three Oral Doses of Laquinimod.
Phase 2. Oral Medication. Duration: 12 months. NCT02215616.
Mild Huntington’s Disease (HD). Age 21-55.
(Dr. Marder) For more information, please contact Paula Wasserman (212) 305-4597, Ronda Clouse (212) 305-2387.

Genetic and Observational Studies Currently Recruiting


Mild Alzheimer's Disease/ Mild Cognitive Impairment/Normal Cognition: Imaging Inflammation in Elders with Different Clinical and Biomarker Profiles of Alzheimer's Disease
Mild Alzheimer's Disease/Mild Cognitive Impairment/Normal Cognition. Age ≥60. Duration: 5 visits.
(Dr. Kreisl) Call Solciris Dominguez (212) 305-9971.

Mild Cognitive Impairment: White Matter and Hippocampal Circuitry (Project 1)
Mild Cognitive Impairment (MCI). Duration: 2 visits, 2.5hrs each visit. CDR 0 or 0.5. Age ≥60.
(Dr. Brickman) Call Christiane Hale (646) 317-4072.

Parkinson's Disease Dementia/Dementia with Lewy Bodies: Imaging Inflammation in Patients with diffuse Lewy body disease
Parkinson's Disease Dementia/Dementia with Lewy Bodies. Age ≥60. Duration: 6 months.
(Dr. Kreisl) Call Solciris Dominguez (212) 305-9971.

Alzheimer's Disease: Assessment and Characterizationof Naming in Older Adults with Epilepsy and PAD
Probable Alzheimer's Disease. MMSE 19-25. Age 56-90. Duration: 90 minutes.
(Dr. Hamberger/Dr. Honig) For more information, please contact call Alicia Williams (212) 305-1801.

Dominantly Inherited Alzheimer Network (DIAN)
The main objective of this study is to learn about brain changes that may occur on people who carry a genetic mutation which causes early onset Alzheimer disease. These participants will receive an annual follow up before they present any symptoms and includes evaluations, mental status testing, MRI and PET scans, blood assays with genetic studies and assays of cerebrospinal fluids.
For more information, please contact Dolly Reyes-Dumeyer (212) 305-5953.

Late Onset Alzheimer Disease Study (LOAD)
The purpose of this study is to identify genes that may increase the risk for developing Alzheime's disease (AD). We are seeking families with at least two living siblings diagnosed with AD who are 60 years or older.
For more information, please contact Pedro Mena (212) 305-2309.

The Study of Alzheimer Disease in Caribbean Hispanic Families
The purpose of this study is to identify genes that may increase the risk for developing Alzheime's disease (AD). We are seeking families and/or individuals who are 60 years or older, with or without memory problems.
For more information, please contact Angel Piriz (212) 305-2309.

Longitudinal Evaluation of Familial Frontotemporal Dementia (LEFFTDS)
This research study aims to identify the most reliable methods to track disease progression in familial Frontotemporal Dementia (FTD) so that clinical trials can be designed appropriately. Members of families in whom at least one member has a known mutation in the MAPT (tau), PGRN (progranulin), or C9orf72 (C9) genes are invited to participate. NCT02372773
For more information, contact Masood Manoochehri at (212) 305-5710 or mm2626@cumc.columbia.edu.

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
The ARTFL consortium supports multiple research projects centered around frontotemporal lobar degeneration (FTLD). Eligible participants may include both individuals diagnosed with an FTLD disorder as well as healthy members of families with an FTLD disorder, such as Frontotemporal Dementia (FTD), Primary Progressive Aphasia (PPA), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration Syndrome (CBD), or Frontotemporal Dementia with Amyotrophic Lateral Sclerosis (FTD-ALS). NCT02365922
For more information, contact Masood Manoochehri at (212) 305-5710 or mm2626@cumc.columbia.edu.

Early Symptoms of Frontotemporal Lobar Degeneration
This research study seeks to evaluate the earliest signs of Frontotemporal Lobar Degeneration and whether lifestyle can modify the progression of the disease. This study is seeking volunteers from families in whom at least one member has a confirmed MAPT mutation of FTLD (also known as the "tau" gene).
For more information, please contact Gayathri Cheran, at (212) 305-1561 or gc2646@cumc.columbia.edu.

Brain Donation Program: “Give the Gift of Knowledge”
Brain donation allows valuable information to be obtained regarding normal aging and diseases that affect memory. This information may be useful towards the goal of developing more effective treatment strategies. If you or a family member wish to learn more about this program.
For more information, please contact Arlene Lawton, RN at (212) 305-9086.

Lucy G. Moses Center for Memory and Behavioral Disorders
Changes in memory and thinking abilities can occur from a variety of conditions, not just Alzheimer’s disease. Taub Institute specialists offer a thorough multidisciplinary evaluation of memory and thinking difficulties. We are located at The Neurological Institute, Columbia University Medical Center, 710 West 168th Street, 3rd Floor, New York.
For appointments, please call (212) 305-6939.



bottom bar